Empaveli

Pharma

Sobi places $300M bet on Empaveli in partnership with Apellis

Sobi will pay partner Apellis $275 million upfront and up to $25 million in potential milestones to reduce its ex-U.S. royalty obligations on Empaveli.

Kevin Dunleavy Jul 1, 2025 11:28am

Apellis' Syfovre faces tough road ahead in GA market: analyst

May 14, 2025 11:10am

Novartis' Fabhalta nod in C3G leaves room for rival Apellis

Mar 21, 2025 10:37am

Apellis' weak quarter could signal Syfovre 'nadir': analysts

Nov 5, 2024 3:41pm

Novartis, Apellis roll out rival datasets in rare kidney disease

Oct 28, 2024 10:03am

Watch out, Novartis. Apellis scores major win in kidney diseases

Aug 8, 2024 2:28pm